Research Article
Detection of Virulence Factors and Antibiotic Resistance among Klebsiella pneumoniae Isolates from Iran
Table 2
Antimicrobial susceptibility test results for K. pneumoniae isolates.
| | Antibiotics () | Sensitive no. (%) | Intermediate no. (%) | Resistant no. (%) |
| | Aztreonam (ATM, 10 μg) | 7 (13.5%) | 12 (23.1%) | 33 (63.5%) | | Gentamicin (GM, 10 μg) | 12 (23.1%) | 8 (15.4%) | 32 (62.5%) | | Ciprofloxacin (CIP, 30 μg) | 5 (9.6%) | 4 (7.7%) | 43 (82.7%) | | Fosfomycin (FOS, 200 μg) | 39 (75%) | 2 (3.8%) | 11 (21.2%) | | Trimethoprim sulfamethoxazole (TS, 30 μg) | 14 (26.9%) | 0 | 38 (73.1%) | | Amikacin (AK, 30 μg) | 14 (26.9%) | 4 (7.7%) | 34 (65.4%) | | Cefotaxime (CTX, 30 μg) | 0 | 4 (7.7%) | 48 (92.3%) | | Ceftazidime (30 μg) | 3 (5.8%) | 2 (3.8%) | 47 (90.4%) | | Cefepime (FEP, 30 μg) | 3 (5.8%) | 15 (28.8%) | 34 (65.4%) | | Nalidixic acid (NA, 30 μg) | 0 | 6 (11.5%) | 46 (88.5%) | | Piperacillin (PIP, 100 μg) | 0 | 2 (3.8%) | 50 (96.2%) | | Minocycline (MN, 15 μg) | 36 (69.2%) | 9 (17.3%) | 7 (13.5%) | | Doripenem (DOR, 10 μg) | 9 (17.3%) | 7 (13.5%) | 36 (69.2%) | | Ertapenem (ETP, 10 μg) | 13 (25%) | 3 (5.8%) | 36 (69.2%) | | Imipenem (IMI, 10 μg) | 15 (28.8%) | 3 (5.8%) | 34 (65.4%) | | Meropenem (MEM, 10 μg) | 22 (42.3%) | 0 | 30 (57.7%) | | Colistin (COL) | 37 (71.2%) | 0 | 15 (28.8%) | | Piperacillin/tazobactam (PTZ, 100/10 μg) | 11 (21.2%) | 7 (13.5%) | 34 (65.4%) |
|
|
